Semaglutide — the key ingredient in Ozempic and Wegovy — had been in shortage since 2022. Now that supply has stabilized, state-licensed compounding pharmacies and physicians must stop selling ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...

Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...

With Novo Nordisk’s blockbuster drugs Wegovy and Ozempic back in stock, copycat versions of semaglutide are no longer allowed ...

The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.

The FDA announcement confirms that the U.S. supply of both prescription-only drugs now meets or exceeds the current and ...

The U.S. Food and Drug Administration said Ozempic and Wegovy, the popular GLP-1 drugs for diabetes and weight loss, are no ...

We will continue to offer access to personalized treatments as allowed by law to meet patient needs,” Hims & Hers CEO said.

Key Takeaways Hims & Hers Health shares swooned after the Food & Drug Administration said the active ingredient in Ozempic ...

The FDA said the shortage of Novo Nordisk's weight-loss drugs Wegovy and Ozempic is resolved. The move could limit cheaper ...

Ozempic and Wegovy, the widely popular forms of semaglutide sold to treat diabetes and obesity, have officially been removed ...

The blistering rally in Hims & Hers Health Inc. that’s captivated meme-stock traders has ground to a halt, setting up a ...